Future prospects in the diagnosis and management of localized prostate cancer

The Scientific World Journal

Volumn 2013, Issue , 2013, Pages

  Tefekli, Ahmet ^a   Tunc, Murat ^b  

^a BAHCESEHIR UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; PROSTATE CANCER GENE 3; PROTEIN; RIBONUCLEASE L; RILIMOGENE GALVACIREPVEC; SIPULEUCEL T; TMPRSS 2 PROTEIN; UNCLASSIFIED DRUG; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER IMMUNIZATION; CANCER LOCALIZATION; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; DIET; DRUG COST; EXTERNAL BEAM RADIOTHERAPY; FUSION GENE; FUTUROLOGY; GENETIC ASSOCIATION; HUMAN; INTERSTITIAL RADIATION; LIFESTYLE MODIFICATION; MALE; MULTIMODALITY CANCER THERAPY; PROSTATE CANCER; PROSTATECTOMY; PROTEIN URINE LEVEL; RISK ASSESSMENT; VIRAL GENE THERAPY; METABOLISM; PATHOLOGY; PROSTATE; PROSTATE TUMOR; REVIEW; PROSTATIC NEOPLASMS;

HUMANS; MALE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84884886049     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1155/2013/347263     Document Type: Article

References (64)

1. Siegel R., Naishadham D., Jemal A., Cancer statistics, 2012. CA: A Cancer Journal for Clinicians 2012 62 1 10 29 2-s2.0-84855792427 10.3322/caac.20138
2. Jani A. B., Johnstone P. A. S., Liauw S. L., Master V. A., Brawley O. W., Age and grade trends in prostate cancer (1974-2003): a surveillance, epidemiology, and end results registry analysis. American Journal of Clinical Oncology 2008 31 4 375 378 2-s2.0-55449088131 10.1097/COC.0b013e3181637384
3. Heidenreich A., Bellmunt J., Bolla M., Joniau S., Mason M., Matveev V., Mottet N., Schmid H.-P., Van Der Kwast T., Wiegel T., Zattoni F., EAU guidelines on prostate cancer-part 1: screening, diagnosis, and treatment of clinically localised disease. European Urology 2011 59 1 61 71 2-s2.0-78649362120 10.1016/j.eururo.2010.10.039
4. Xia J., Gulati R., Au M., Gore J. L., Lin D. W., Etzioni R., Effects of screening on radical prostatectomy efficacy: the prostate cancer intervention versus observation trial. The Journal of the National Cancer Institute 2013 105 8 546 550
5. Killick E., Bancroft E., Kote-Jarai Z., Eeles R., Beyond prostate-specific antigen-future biomarkers for the early detection and management of prostate cancer. Clinical Oncology 2012 24 8 545 555 10.1016/j.clon.2012.05.001
6. Catalona W. J., Partin A. W., Sanda M. G., Wei J. T., Klee G. G., Bangma C. H., Slawin K. M., Marks L. S., Loeb S., Broyles D. L., Shin S. S., Cruz A. B., Chan D. W., Sokoll L. J., Roberts W. L., Van Schaik R. H. N., Mizrahi I. A., A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. Journal of Urology 2011 185 5 1650 1655 2-s2.0-79953777963 10.1016/j.juro.2010.12.032
7. Catalona W. J., Bartsch G., Rittenhouse H. G., Evans C. L., Linton H. J., Horninger W., Klocker H., Mikolajczyk S. D., Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. Journal of Urology 2004 171 6, part 1 2239 2244 2-s2.0-2442600143 10.1097/01.ju.0000127737.94221.3e (Pubitemid 38625443)
8. Stephan C., Kahrs A.-M., Cammann H., Lein M., Schrader M., Deger S., Miller K., Jung K., A [-2] pro PSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases. Prostate 2009 69 2 198 207 2-s2.0-58849091840 10.1002/pros.20872
9. Makarov D. V., Isharwal S., Sokoll L. J., Landis P., Marlow C., Epstein J. I., Partin A. W., Carter H. B., Veltri R. W., Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer. Clinical Cancer Research 2009 15 23 7316 7321 2-s2.0-73149087871 10.1158/1078-0432.CCR-09-1263
10. Shariat S. F., Semjonow A., Lilja H., Savage C., Vickers A. J., Bjartell A., Tumor markers in prostate cancer I: blood-based markers. Acta Oncologica 2011 50 supplement 1 61 75 2-s2.0-79957461212 10.3109/0284186X.2010.542174
11. Wilt T. J., Brawer M. K., Jones K. M., Radical prostatectomy versus observation for localized prostate cancer. The New England Journal of Medicine 2012 367 3 203 213 10.1056/NEJMoa1113162
12. Andriole G. L., Crawford E. D., Grub R. L., Mortality results from a randomized prostate cancer screening trial. The New England Journal of Medicine 2009 360 13 1310 1319 10.1056/NEJMoa0810696
13. Schröder F. H., Hugosson J., Roobol M. J., Tammela T. L. J., Ciatto S., Nelen V., Kwiatkowski M., Lujan M., Lilja H., Zappa M., Denis L. J., Recker F., Määpttänen A. B., Bangma C. H., Aus G., Villers A., Rebillard X., Van Kwast T. D., Blijenberg B. G., Moss S. M., De Koning H. J., Auvinen A., Screening and prostate-cancer mortality in a randomized european study. The New England Journal of Medicine 2009 360 13 1320 1328 2-s2.0-63249118690 10.1056/NEJMoa0810084
14. Heidenreich A., Abrahamsson P. A., Artibani W., Early detection of prostate cancer: European association of urology recommendation. European Urology 2013 64 3 347 354 10.1016/j.eururo.2013.06.051
15. Wolf A. M., Wender R. C., Etzioni R. B., American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA: A Cancer Journal for Clinicians 2010 60 2 70 98 10.3322/caac.20066
16. Popiolek M., Rider J. R., Andrén O., Andersson S. O., Holmberg L., Adami H. O., Johansson J. E., Natural history of early, localized prostate cancer: a final report from three decades of follow-up. European Urology 2013 63 3 428 435 10.1016/j.eururo.2012.10.002
17. Carter H. B., Albertsen P. C., Barry M. J., Early detection of prostate cancer: AUA guideline. The Journal of Urology 2013 190 2 419 426 10.1016/j.juro.2013.04.119
18. Moyer V. A., U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Annals of Internal Medicine 2012 157 2 120 134
19. Artibani W., Landmarks in prostate cancer diagnosis: the biomarkers. BJU International 2012 110 supplement 1 8 13 10.1111/j.1464-410X.2012.011429.x
20. Bjartell A., Montironi R., Berney D. M., Egevad L., Tumour markers in prostate cancer II: diagnostic and prognostic cellular biomarkers. Acta Oncologica 2011 50 supplement 1 76 84 2-s2.0-79957456529 10.3109/0284186X.2010. 531284
21. Roobol M. J., Haese A., Bjartell A., Tumour markers in prostate cancer III: biomarkers in urine. Acta Oncologica 2011 50 supplement 1 85 89 2-s2.0-79957520906 10.3109/0284186X.2010.524935
22. Auprich M., Bjartell A., Chun F. K.-H., De La Taille A., Freedland S. J., Haese A., Schalken J., Stenzl A., Tombal B., Van Der Poel H., Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. European Urology 2011 60 5 1045 1054 2-s2.0-80053315206 10.1016/j.eururo.2011.08.003
23. Hessels D., Klein Gunnewiek J. M., van Oort I., DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. European Urology 2003 44 1 8 15
24. van Gils M. P. M. Q., Hessels D., van Hooij O., Jannink S. A., Peelen W. P., Hanssen S. L. J., Witjes J. A., Cornel E. B., Karthaus H. F. M., Smits G. A. H. J., Dijkman G. A., Mulders P. F. A., Schalken J. A., The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clinical Cancer Research 2007 13 3 939 943 2-s2.0-33847397812 10.1158/1078-0432.CCR-06-2679 (Pubitemid 46340370)
25. Auprich M., Haese A., Walz J., Pummer K., De La Taille A., Graefen M., De Reijke T., Fisch M., Kil P., Gontero P., Irani J., Chun F. K.-H., External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome. European Urology 2010 58 5 727 732 2-s2.0-77957575094 10.1016/j.eururo.2010.06.038
26. Salagierski M., Schalken J. A., Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion. Journal of Urology 2012 187 3 795 801 2-s2.0-84857044547 10.1016/j.juro.2011.10.133
27. Perner S., Mosquera J.-M., Demichelis F., Hofer M. D., Paris P. L., Simko J., Collins C., Bismar T. A., Chinnaiyan A. M., De Marzo A. M., Rubin M. A., TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. American Journal of Surgical Pathology 2007 31 6 882 888 2-s2.0-34447342868 10.1097/01.pas.0000213424.38503.aa (Pubitemid 47165141)
28. Alvarez-Cubero M. J., Saiz M., Martinez-Gonzalez L. J., Alvarez J. C., Lorente J. A., Cozar J. M., Genetic analysis of the principal genes related to prostate cancer: a review. Urologic Oncology 2012 10.1016/j.urolonc.2012.07.011
29. Alvarez-Cubero M. J., Saiz M., Martinez-Gonzalez L. J., Alvarez J. C., Lorente J. A., Cozar J. M., Genetic analysis of the principal genes related to prostate cancer: a review. Urologic Oncology 2012 10.1016/j.urolonc.2012.07.011
30. Schmalfuss F., Kolominsky-Rabas P. L., Personalized medicine in screening for malignant disease: a review of methods and applications. Biomark Insights 2013 8 9 14
31. Bastian P. J., Boorjian S. A., Bossi A., Briganti A., Heidenreich A., Freedland S. J., Montorsi F., Roach M. III, Schröder F., Van Poppel H., Stief C. G., Stephenson A. J., Zelefsky M. J., High-risk prostate cancer: from definition to contemporary management. European Urology 2012 61 6 1096 1106 2-s2.0-84860281050 10.1016/j.eururo.2012.02.031
32. Dijkstra S., Hamid A. R., Leyten G. H., Schalken J. A., Personalized management in low-risk prostate cancer: the role of biomarkers. Prostate Cancer 2012 2012 7 10.1155/2012/327104 327104
33. Karanikolas B. D. W., Figueiredo M. L., Wu L., Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines. Prostate 2010 70 6 675 688 2-s2.0-77950874502 10.1002/pros.21112
34. Kochanek S., Gansbacher B., Prostate cancer gene therapy: attempts to innovate. Human Gene Therapy 2010 21 7 791 2-s2.0-77957933901
35. Ahmed K. A., Davis B. J., Wilson T. M., Wiseman G. A., Federspiel M. J., Morris J. C., Progress in gene therapy for prostate cancer. Frontiers in Oncology 2012 2 article 172
36. Fukuhara H., Homma Y., Todo T., Oncolytic virus therapy for prostate cancer: review article. International Journal of Urology 2010 17 1 20 30 2-s2.0-74049123530 10.1111/j.1442-2042.2009.02383.x
37. Msaouel P., Iankov I. D., Allen C., Morris J. C., Von Messling V., Cattaneo R., Koutsilieris M., Russell S. J., Galanis E., Engineered measles virus as a novel oncolytic therapy against prostate cancer. Prostate 2009 69 1 82 91 2-s2.0-58149345608 10.1002/pros.20857
38. Kawalec P., Paszulewicz A., Holko P., Pilc A., Sipuleucel-T immunotherapy for castration-resistant prostate cancer. A systematic review and meta-analysis. Archives of Medical Science 2012 8 5 767 775 10.5114/aoms.2012. 31610
39. Madan R. A., Arlen P. M., Mohebtash M., Hodge J. W., Gulley J. L., Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opinion on Investigational Drugs 2009 18 7 1001 1011 10.1517/13543780902997928
40. Ligibel J., Lifestyle factors in cancer survivorship. Journal of Clinical Oncology 2012 30 30 3697 3704 10.1200/JCO.2012.42.0638
41. Paller C. J., Ye X., Wozniak P. J., Gillespie B. K., Sieber P. R., Greengold R. H., Stockton B. R., Hertzman B. L., Efros M. D., Roper R. P., Liker H. R., Carducci M. A., A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localizedprostate cancer. Prostate Cancer and Prostatic Diseases 2013 16 1 50 55 10.1038/pcan.2012.20
42. Kroeger N., Belldegrun A. S., Pantuck A. J., Pomegranate extracts in the management of men's urologic health: scientific rationale and preclinical and clinical data. Evidence-Based Complementary and Alternative Medicine 2013 2013 9 10.1155/2013/701434 701434
43. Azrad M., Vollmer R. T., Madden J., Dewhirst M., Polascik T. J., Snyder D. C., Ruffin M. T., Moul J. W., Brenner D. E., Flaxseed-derived enterolactone is inversely associated with tumor cell proliferation in men with localized prostate cancer. Journal of Medicinal Food 2013 16 4 357 360 10.1089/jmf.2012.0159
44. Demark-Wahnefried W., Polascik T. J., George S. L., Switzer B. R., Madden J. F., Ruffin M. T. IV, Snyder D. C., Owzar K., Hars V., Albala D. M., Walther P. J., Robertson C. N., Moul J. W., Dunn B. K., Brenner D., Minasian L., Stella P., Vollmer R. T., Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery. Cancer Epidemiology Biomarkers and Prevention 2008 17 12 3577 3587 2-s2.0-57449111513 10.1158/1055-9965.EPI-08-0008
45. Berkow S. E., Barnard N. D., Saxe G. A., Ankerberg-Nobis T., Diet and survival after prostate cancer diagnosis. Nutrition Reviews 2007 65 9 391 403 2-s2.0-38449106679 10.1301/nr.2007.sept.391-403 (Pubitemid 351804347)
46. Gravas S., Mamoulakis C., Rioja J., Tzortzis V., de Reijke T., Wijkstra H., de la Rosette J., Advances in ultrasound technology in oncologic urology. Urologic Clinics of North America 2009 36 2 133 145 2-s2.0-65249137065 10.1016/j.ucl.2009.02.006
47. Boonsirikamchai P., Choi S., Frank S. J., Ma J., Elsayes K. M., Kaur H., Choi H., MR imaging of prostate cancer in radiation oncology: what radiologists need to know. Radiographics 2013 33 3 741 761 10.1148/rg.333125041
48. Ahmed H. U., Multiparametric magnetic resonance imaging findings in men with low-risk prostate cancer followed using active surveillance. BJU International 2013 111 7 1011 1013 10.1111/j.1464-410X.2012.11786.x
49. Dickinson L., Ahmed H. U., Allen C., Clinical applications of multiparametric MRI within the prostate cancer diagnostic pathway. Urologic Oncology 2013 31 3 281 284
50. Gee M. S., Harisinghani M. G., Tabatabaei S., Molecular imaging in urologic surgery. Urologic Clinics of North America 2009 36 2 125 132 2-s2.0-65249112717 10.1016/j.ucl.2009.02.007
51. Kuru T. H., Roethke M. C., Seidenader J., Simpfendörfer T., Boxler S., Alammar K., Rieker P., Popeneciu V. I., Roth W., Pahernik S., Schlemmer H. P., Hohenfellner M., Hadaschik B. A., Critical evaluation of MRI-targeted TRUS-guided transperineal fusion biopsy for detection of prostate cancer. The Journal of Urology 2013 10.1016/j.juro.2013.04.043
52. Gee M. S., Harisinghani M. G., Tabatabaei S., Molecular imaging in urologic surgery. Urologic Clinics of North America 2009 36 2 125 132 2-s2.0-65249112717 10.1016/j.ucl.2009.02.007
53. Overduin C. G., Fütterer J. J., Barentsz J. O., MRI-guided biopsy for prostate cancer detection: a systematic review of current clinical results. Current Urology Reports 2013 14 3 209 213
54. Bill-Axelson A., Holmberg L., Filén F., Ruutu M., Garmo H., Busch C., Nordling S., Häggman M., Andersson S.-O., Bratell S., Spångberg A., Palmgren J., Adami H.-O., Johansson J.-E., Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. Journal of the National Cancer Institute 2008 100 16 1144 1154 2-s2.0-51049104630 10.1093/jnci/djn255
55. Klotz L., Active surveillance for low-risk prostate cancer. Medicine Reports 2012 4 article 16 10.3410/M4-16
56. Dall'Era M. A., Albertsen P. C., Bangma C., Carroll P. R., Carter H. B., Cooperberg M. R., Freedland S. J., Klotz L. H., Parker C., Soloway M. S., Active surveillance for prostate cancer: a systematic review of the literature. European Urology 2012 62 976 983
57. Mullins J. K., Feng Z., Trock B. J., Epstein J. I., Walsh P. C., Loeb S., The impact of anatomical radical retropubic prostatectomy on cancer control: the 30-year anniversary. Journal of Urology 2012 188 6 2219 2224
58. Montorsi F., Wilson T. G., Rosen R. C., Ahlering T. E., Artibani W., Carroll P. R., Costello A., Eastham J. A., Ficarra V., Guazzoni G., Menon M., Novara G., Patel V. R., Stolzenburg J. U., Van der Poel H., Van Poppel H., Mottrie A., Best practices in robot-assisted radical prostatectomy: recommendations of the Pasadena Consensus Panel. European Urology 2012 62 3 368 381 10.1016/j.eururo.2012.05.057
59. Bianco F. J. Jr., Scardino P. T., Eastham J. A., Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ("trifecta"). Urology 2005 66 supplement 5 83 94 2-s2.0-25144458366 10.1016/j.urology.2005.06.116 (Pubitemid 41356564)
60. Patel V. R., Sivaraman A., Coelho R. F., Chauhan S., Palmer K. J., Orvieto M. A., Camacho I., Coughlin G., Rocco B., Pentafecta: a new concept for reporting outcomes of robot-assisted laparoscopic radical prostatectomy. European Urology 2011 59 5 702 707 2-s2.0-79953252756 10.1016/j.eururo.2011.01. 032
61. Ficarra V., Sooriakumaran P., Novara G., Schatloff O., Briganti A., Van Der Poel H., Montorsi F., Patel V., Tewari A., Mottrie A., Systematic review of methods for reporting combined outcomes after radical prostatectomy and proposal of a novel system: the survival, continence, and potency (SCP) classification. European Urology 2012 61 3 541 548 2-s2.0-84856388875 10.1016/j.eururo.2011.11. 042
62. Morton G. C., Loblaw D. A., Sankreacha R., Deabreu A., Zhang L., Mamedov A., Cheung P., Keller B., Danjoux C., Szumacher E., Thomas G., Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life. International Journal of Radiation Oncology Biology Physics 2010 77 3 811 817 2-s2.0-77952573175 10.1016/j.ijrobp.2009.05. 054
63. Aoyama H., Azuma Y., Inamura K., Comparison of daily prostate positions during conformal radiation therapy of prostate cancer using an integrated CT-linear accelerator system: in-room CT image versus digitally reconstructed radiograph. Journal of Radiation Research 2011 52 2 220 228 2-s2.0-79953154015 10.1269/jrr.10111
64. Bozzini G., Colin P., Nevoux P., Villers A., Mordon S., Betrouni N., Focal therapy of prostate cancer: energies and procedures. Urologic Oncology 2013 31 2 155 167